Core I97L mutation in conjunction with P79Q is associated with persistent low HBV DNA and HBs antigen clearance in patients with chronic hepatitis B

Dienstag, 2008, Hepatitis B virus infection, N Engl J Med, 359, 1486, 10.1056/NEJMra0801644 Hoofnagle, 2007, Management of hepatitis B: summary of a clinical research workshop, Hepatology, 45, 1056, 10.1002/hep.21627 Lok, 2009, Chronic hepatitis B: update 2009, Hepatology, 50, 661, 10.1002/hep.23190 Liaw, 2009, Hepatitis B virus infection, Lancet, 373, 582, 10.1016/S0140-6736(09)60207-5 EASL clinical practice guidelines, 2012, management of chronic hepatitis B virus infection, J Hepatol, 57, 167, 10.1016/j.jhep.2012.02.010 Hsu, 2002, Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B, Hepatology, 35, 1522, 10.1053/jhep.2002.33638 Chen, 2002, Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection, Gastroenterology, 123, 1084, 10.1053/gast.2002.36026 Arase, 2006, Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B, Am J Med, 119, 10.1016/j.amjmed.2005.02.033 Yuen, 2002, Relationship between the development of precore and core promoter mutations and hepatitis B e antigen seroconversion in patients with chronic hepatitis B virus, J Infect Dis, 186, 1335, 10.1086/344327 Carman, 1989, Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection, Lancet, 2, 588, 10.1016/S0140-6736(89)90713-7 Marcellin, 2004, Peginterferon α-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B, N Engl J Med, 351, 1206, 10.1056/NEJMoa040431 Janssen, 2005, Pegylated interferon α-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial, Lancet, 365, 123, 10.1016/S0140-6736(05)17701-0 Feld, 2007, Evolution of therapy for chronic hepatitis B: progressing from the simple to the complex, Ann Intern Med, 147, 806, 10.7326/0003-4819-147-11-200712040-00014 Chang, 2010, Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B, Hepatology, 51, 422, 10.1002/hep.23327 Woo, 2010, Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses, Gastroenterology, 139, 1218, 10.1053/j.gastro.2010.06.042 2014, JSH Guidelines for the Management of Hepatitis B Virus Infection, Hepatol Res, 44, 1 Gunther, 1995, A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients, J Virol, 69, 5437, 10.1128/JVI.69.9.5437-5444.1995 Kanada, 2007, Type B fulminant hepatitis is closely associated with a highly mutated hepatitis B virus strain, Intervirology, 50, 394, 10.1159/000110651 Ehata, 1992, Variations in codons 84–101 in the core nucleotide sequence correlate with hepatocellular injury in chronic hepatitis B virus infection, J Clin Invest, 89, 332, 10.1172/JCI115581 Ehata, 1993, Mutations in core nucleotide sequence of hepatitis B virus correlate with fulminant and severe hepatitis, J Clin Invest, 91, 1206, 10.1172/JCI116281 Bozkaya, 1996, High rate of mutations in the hepatitis B core gene during the immune clearance phase of chronic hepatitis B virus infection, Hepatology, 24, 32, 10.1002/hep.510240107 Akarca, 1995, Naturally occurring hepatitis B virus core gene mutations, Hepatology, 22, 50 Kim, 2012, Naturally occurring precore/core region mutations of hepatitis B virus genotype C related to hepatocellular carcinoma, PLoS One, 7, e47372, 10.1371/journal.pone.0047372 Liu, 2011, Effects of hepatitis B virus precore and basal core promoter mutations on the expression of viral antigens: genotype B vs C, J Viral Hepat, 18, e482, 10.1111/j.1365-2893.2011.01480.x Ning, 2004, Nucleolar localization of human hepatitis B virus capsid protein, J Virol, 78, 13653, 10.1128/JVI.78.24.13653-13668.2004 Packianathan, 2010, Conformational changes in the hepatitis B virus core protein are consistent with a role for allostery in virus assembly, J Virol, 84, 1607, 10.1128/JVI.02033-09